ClinicalTrials.gg
CompletedNCT03891862Updated Apr 20, 2021Results posted

Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

A Phase 4 interventional study of Valbenazine and Placebo oral capsule in Tardive Dyskinesia (TD), sponsored by Neurocrine Biosciences. Completed at 43 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-04-20.

Sponsored by Neurocrine Biosciences · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing valbenazine in Tardive Dyskinesia — 1 open to participants now, 1 under way, none of them phase 3. valbenazine · Tardive Dyskinesia.

Enrollment
5th of 14
135 · median 101
Started
2019
the only one that year
Phase 4
5 of 14
1 open now
Registered
10th of 14
by date
Lead sponsor
11 of 14
Neurocrine Biosciences

Among the 14 studies testing valbenazine in Tardive Dyskinesia, this one is the 5th largest by enrollment, is the only one that started in 2019, is one of 5 in phase 4, and was the 10th registered.

Tardive Dyskinesia

62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.

Browse Tardive Dyskinesia studies →

Open to participants now

1 of the 14 studies testing valbenazine in Tardive Dyskinesia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About valbenazine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing valbenazine in Tardive Dyskinesia, or all of them as a file.
02

Study summary

This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the persistence of effect of valbenazine 40 mg and 80 mg.

03

Conditions studied

  • Tardive Dyskinesia (TD)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects of must agree to use hormonal or two forms of nonhormonal (dual contraception) consistently during the screening, treatment, and follow-up periods of the study.
  2. Have one of the following clinical diagnoses for at least 3 months before screening: Schizophrenia, Schizoaffective Disorder, or Mood Disorder
  3. Have a clinical diagnosis of neuroleptic-induced TD for at least 3 months before screening.
  4. Be on stable doses if using maintenance medication(s) for schizophrenia or schizoaffective disorder, or mood disorder. Subjects with bipolar disorder must be on stable doses of a mood stabilizer.
  5. Be in general good health.
  6. Have adequate hearing, vision, and language skills to perform the procedures specified in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Have an active, unstable medical condition within 1 month before screening.
  2. Have a known history of substance (drug) dependence, or substance or alcohol abuse.
  3. Have a significant risk of suicidal or violent behavior.
  4. Have been hospitalized for psychiatric disorder within 6 months before Day 1.
  5. Have a known history of neuroleptic malignant syndrome.
  6. Have a known history of long syndrome or cardiac arrhythmia.
  7. Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed).
  8. Are currently taking tetrabenazine or deutetrabenazine, or have used valbenazine (INGREZA) within 30 days of screening.
  9. Have received an drug within 30 days before Day 1 or plan to use an investigational drug (other than NBI-98854) during the study.
  10. Have a blood loss ≥550 mL or donated blood within 30 days prior to Baseline.
  11. Have an allergy, , or intolerance to VMAT2 inhibitors (eg, tetrabenazine, deutetrabenazine).
  12. Are currently pregnant or breastfeeding.
  13. Have or .
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Open-label Valbenazine

    Participants received valbenazine 40 mg once daily for 1 week, then 80 mg once daily for the remainder of the 8-week open label period.

    Drug: Valbenazine

  • Placebo comparator
    Placebo-controlled Placebo

    Participants received placebo (matching valbenazine) once daily for 8 weeks. Randomization into this arm occurred after open-label treatment with valbenazine once daily for 8 weeks.

    Drug: Placebo oral capsule

  • Experimental
    Placebo-controlled Valbenazine

    Participants received valbenazine 80 mg once daily for 8 weeks. Randomization into this arm occurred after open-label treatment with valbenazine once daily for 8 weeks.

    Drug: Valbenazine

Interventions

  • vesicular monoamine transporter 2 (VMAT2) inhibitor

    Also known as: Ingrezza, NBI-98854

  • DrugPlacebo oral capsule

    non-active dosage form

06

What researchers measure

Primary outcomes

  1. Change From Randomization (Week 8) in Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score at Week 16

    The AIMS rates 10 items of involuntary movement, each item ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Items assess facial, oral, extremity, and trunk movements, as well as self-awareness of abnormal movements. The AIMS Dyskinesia Total Score is the sum of items 1-7 and ranges from 0 to 28, with higher scores indicating more severe dyskinesia. Least-squares mean were estimated using a mixed-effects model for repeated measures.

    Time frame: Week 8, Week 16

Secondary outcomes

  1. Change From Baseline in the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Health State Index Score at Week 16

    The EQ-5D-5L assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The health state index score is based on the results of the individual health profiles using the United States value set and ranges from -0.573 to 1.0, with higher scores indicating higher health utility.

    Time frame: Baseline, Week 16

  2. Change From Baseline in the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) at Week 16

    The EQ-5D-5L assesses general health-related quality of life. The second portion of the scale is a self-perceived health score assessed using a VAS that ranges from 0 ("the worst imaginable health") to 100 ("the best imaginable health").

    Time frame: Baseline, Week 16

07

Results

Posted Mar 10, 2021

Participant flow

The study enrolled male and female participants, 18 to 85 years of age, from 28 centers in the United States. Participants must have clinical diagnoses of schizophrenia or schizoaffective disorder with neuroleptic-induced tardive dyskinesia (TD) or mood disorder with neuroleptic-induced TD and have moderate or severe TD as assessed by an external Abnormal Involuntary Movement Scale (AIMS) Reviewer. The first and last participant was enrolled on 18 March 2019 and 3 September 2019, respectively.

Open-label Period
Participant flow — Open-label Period
MilestoneOpen-label ValbenazinePlacebo-controlled PlaceboPlacebo-controlled Valbenazine
Started13500
Safety analysis set13200
Completed11900
Not completed1600
Withdrew: Adverse event200
Withdrew: Protocol violation500
Withdrew: Withdrawal by subject600
Withdrew: Death100
Withdrew: Lost to follow-up200
Placebo-controlled Period and Follow-up
Participant flow — Placebo-controlled Period and Follow-up
MilestoneOpen-label ValbenazinePlacebo-controlled PlaceboPlacebo-controlled Valbenazine
Started05959
Persistence of effect analysis set05859
Completed placebo-controlled period05356
Completed05355
Not completed064
Withdrew: Adverse event011
Withdrew: Protocol violation021
Withdrew: Withdrawal by subject012
Withdrew: Lost to follow-up020

Outcome measures

PrimaryChange From Randomization (Week 8) in Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score at Week 16

The AIMS rates 10 items of involuntary movement, each item ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Items assess facial, oral, extremity, and trunk movements, as well as self-awareness of abnormal movements. The AIMS Dyskinesia Total Score is the sum of items 1-7 and ranges from 0 to 28, with higher scores indicating more severe dyskinesia. Least-squares mean were estimated using a mixed-effects model for repeated measures.

Time frame:
Week 8, Week 16
Reported as:
Least squares mean · Score on scale
Change From Randomization (Week 8) in Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score at Week 16
Score on scalePlacebo-controlled PlaceboPlacebo-controlled Valbenazine
Change From Randomization (Week 8) in Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score at Week 160.6 (-0.8 to 1.9)-1.6 (-3.0 to -0.3)
SecondaryChange From Baseline in the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Health State Index Score at Week 16

The EQ-5D-5L assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The health state index score is based on the results of the individual health profiles using the United States value set and ranges from -0.573 to 1.0, with higher scores indicating higher health utility.

Time frame:
Baseline, Week 16
Reported as:
Mean · Score on scale
Change From Baseline in the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Health State Index Score at Week 16
Score on scalePlacebo-controlled PlaceboPlacebo-controlled Valbenazine
Change From Baseline in the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Health State Index Score at Week 160.09 ± 0.030.16 ± 0.03
SecondaryChange From Baseline in the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) at Week 16

The EQ-5D-5L assesses general health-related quality of life. The second portion of the scale is a self-perceived health score assessed using a VAS that ranges from 0 ("the worst imaginable health") to 100 ("the best imaginable health").

Time frame:
Baseline, Week 16
Reported as:
Mean · Score on scale
Change From Baseline in the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) at Week 16
Score on scalePlacebo-controlled PlaceboPlacebo-controlled Valbenazine
Change From Baseline in the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) at Week 164.5 ± 2.56.5 ± 2.8

Adverse events

Collected over Open-label valbenazine group: from baseline up to randomization (Week 8). Placebo-controlled placebo and valbenazine groups: from randomization (Week 8) up to Week 20. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open-label Valbenazine1/132 (0.8%)3/132 (2.3%)17/132 (12.9%)
Placebo-controlled Placebo0/59 (0%)2/59 (3.4%)11/59 (18.6%)
Placebo-controlled Valbenazine0/59 (0%)1/59 (1.7%)7/59 (11.9%)
Most frequent serious events
Most frequent serious events
EventOpen-label ValbenazinePlacebo-controlled PlaceboPlacebo-controlled Valbenazine
CellulitisInfections and infestations0/1321/590/59
SepsisInfections and infestations0/1321/590/59
Psychotic disorderPsychiatric disorders0/1321/590/59
Knee arthroplastySurgical and medical procedures0/1320/591/59
Accidental overdoseInjury, poisoning and procedural complications1/1320/590/59
DehydrationMetabolism and nutrition disorders1/1320/590/59
SyncopeNervous system disorders1/1320/590/59
Most frequent other events
Most frequent other events
EventOpen-label ValbenazinePlacebo-controlled PlaceboPlacebo-controlled Valbenazine
Urinary tract infectionInfections and infestations4/1326/590/59
Pain in extremityMusculoskeletal and connective tissue disorders5/1320/590/59
AnaemiaBlood and lymphatic system disorders1/1322/591/59
FallInjury, poisoning and procedural complications2/1322/590/59
Blood creatine phosphokinase increasedInvestigations1/1320/592/59
Blood glucose increasedInvestigations0/1320/592/59
Weight increasedInvestigations2/1320/592/59
Suicidal ideationPsychiatric disorders1/1322/591/59
SomnolenceNervous system disorders4/1320/590/59

Baseline characteristics

Persistence of effect analysis set, which includes all randomized participants who received at least one dose of randomized study drug and have at least one AIMS assessment during the placebo-controlled period.

Age, Continuous
Age, Continuous(Years)Placebo-controlled PlaceboPlacebo-controlled ValbenazineTotal
Mean59.2 ± 8.358.0 ± 8.058.6 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)Placebo-controlled PlaceboPlacebo-controlled ValbenazineTotal
Female273057
Male312960
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo-controlled PlaceboPlacebo-controlled ValbenazineTotal
Hispanic or Latino323264
Not Hispanic or Latino262753
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo-controlled PlaceboPlacebo-controlled ValbenazineTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American211637
White364379
More than one race101
Unknown or Not Reported000
Abnormal Involuntary Movement Scale at Study Baseline
Abnormal Involuntary Movement Scale at Study Baseline(Score on scale)Placebo-controlled PlaceboPlacebo-controlled ValbenazineTotal
Mean10.3 ± 3.711.0 ± 4.110.7 ± 3.9
08

Study locations

43 sites
  • Neurocrine Clinical Site
    Little Rock, Arkansas 72211, United States
  • Neurocrine Clinical Site
    Anaheim, California 92804, United States
  • Neurocrine Clinical Site
    Anaheim, California 92805, United States
  • Neurocrine Clinical Site
    Costa Mesa, California 92627, United States
  • Neurocrine Clinical Site
    Escondido, California 92056, United States
  • Neurocrine Clinical Site
    Fountain Valley, California 92708, United States
  • Neurocrine Clinical Site
    Glendale, California 91206, United States
  • Neurocrine Clinical Site
    La Habra, California 90631, United States
  • Neurocrine Clinical Site
    Lemon Grove, California 91945, United States
  • Neurocrine Clinical Site
    Norwalk, California 90650, United States
  • Neurocrine Clinical Site
    San Bernardino, California 92408, United States
  • Neurocrine Clinical Site
    San Diego, California 92108, United States
  • Neurocrine Clinical Site
    Torrance, California 90502, United States
  • Neurocrine Clinical Site
    Pueblo, Colorado 81003, United States
  • Neurocrine Clinical Site
    Hialeah, Florida 33012, United States
  • Neurocrine Clinical Site
    Hialeah, Florida 33013, United States
  • Neurocrine Clinical Site
    Hialeah, Florida 33018, United States
  • Neurocrine Clinical Site
    Miami, Florida 33183, United States
  • Neurocrine Clinical Site
    North Miami, Florida 33161, United States
  • Neurocrine Clinical Site
    Orlando, Florida 32803, United States
  • Neurocrine Clinical Site
    South Bend, Indiana 46601, United States
  • Neurocrine Clinical Site
    Bloomfield Hills, Michigan 48302, United States
  • Neurocrine Clinical Site
    East Lansing, Michigan 48824, United States
  • Neurocrine Clinical Site
    Grand Rapids, Michigan 49503, United States
  • Neurocrine Clinical Site
    Kansas City, Missouri 64108, United States
  • Neurocrine Clinical Site
    Saint Louis, Missouri 63109, United States
  • Neurocrine Clinical Site
    Lincoln, Nebraska 68526, United States
  • Neurocrine Clinical Site
    Las Vegas, Nevada 89102, United States
  • Neurocrine Clinical Site
    New York, New York 10029, United States
  • Neurocrine Clinical Site
    Beachwood, Ohio 44122, United States
  • Neurocrine Clinical Site
    Mason, Ohio 45040, United States
  • Neurocrine Clinical Site
    Oklahoma City, Oklahoma 73112, United States
  • Neurocrine Clinical Site
    Conshohocken, Pennsylvania 19428, United States
  • Neurocrine Clinical Site
    Scranton, Pennsylvania 18503, United States
  • Neurocrine Clinical Site
    Franklin, Tennessee 37067, United States
  • Neurocrine Clinical Site
    DeSoto, Texas 75115, United States
  • Neurocrine Clinical Site
    Houston, Texas 44030, United States
  • Neurocrine Clinical Site
    Houston, Texas 77058, United States
  • Neurocrine Clinical Site
    Irving, Texas 75062, United States
  • Neurocrine Clinical Site
    Richmond, Texas 77407, United States
  • Neurocrine Clinical Site
    Petersburg, Virginia 23805, United States
  • Neurocrine Clinical Site
    Spokane, Washington 99202, United States
  • Neurocrine Clinical Site
    San Juan, 00926, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Dec 2019, 9 months.

Results were first posted in Mar 2021, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2019
First posted
Mar 27, 2019
StartActual
Mar 18, 2019
Primary completionActual
Dec 23, 2019
CompletionActual
Jan 30, 2020
Results first posted
Mar 10, 2021
Last update
Apr 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03891862
Responsible party
Sponsor
First posted
Mar 27, 2019
Start date
Mar 18, 2019
Primary completion
Dec 23, 2019
Completion
Jan 30, 2020
Results posted
Mar 10, 2021
Last update
Apr 20, 2021

Study contacts

Chief Medical Officer
study director · Chief Medical Officer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valbenazine

Start the discussion